No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SNSE Sensei Biotherapeutics
- 0.610
- -0.028-4.43%
Trading Jun 17 14:06 ET
15.30MMarket Cap-504P/E (TTM)
0.657High0.602Low42.67KVolume0.631Open0.638Pre Close26.59KTurnover0.26%Turnover RatioLossP/E (Static)25.08MShares1.94052wk High0.26P/B10.02MFloat Cap0.51052wk Low--Dividend TTM16.43MShs Float26.500Historical High--Div YieldTTM8.55%Amplitude0.510Historical Low0.623Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Sensei Biotherapeutics Inc : Citigroup Resumes Coverage With Buy Rating; Target Price $4
Express News | Citigroup Reinstates Buy on Sensei Biotherapeutics, Announces $4 Price Target
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersCue Health (NASDAQ:HLTH) stock moved upwards by 32.4% to $0.12 during Monday's pre-market session. The market value of their outstanding shares is at $19.8 million. SCWorx (NASDAQ:WORX) shares
Sensei Stock Plunges 46% in Wake of Phase 1 Data
LIDR, HOOK and BCAB Among Mid-day Movers
Comments
$Sensei Biotherapeutics(SNSE.US$ anyone got any insights why? shoed FDA phase 1 approved.
1
$Sensei Biotherapeutics(SNSE.US$ Sensei Biotherapeutics Inc: Reported Encouraging Clinical Data From Dose Escalation Portion of Its Phase 1/2 Trial of Sns-101
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...
4
9
$Sensei Biotherapeutics(SNSE.US$ • There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...
2
$Sensei Biotherapeutics(SNSE.US$ can we push pass 1.9 and go 2 onwards
2
1
Revolutionary Cancer Treatment on the Horizon: How Sensei Biotherapeutics' SNS-101 Could Change the Game.
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
maddhatter : It’s a long position for any real profits. They are
a serious cutting edge company. What’ll they actually do? Who knows. Cancer is a tough opponent…